- Hamacher's Dave Wendland to moderate DSN Diabetes & Chronic Care Roundtable for 10th-consecutive year
- Diabetics constantly on the look-out for new ways to manage disease
- Study: Type 2 diabetes market competition heats up amid disease rate increase
- Sam's Club donates $1.25 million to expand YMCA health, wellness initiatives; retailer offers diabetes screenings
- Abbott launches Glucerna Advance RTD to provide nutritional benefits for those with diabetes
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for Type 2 diabetes, the agency said Monday.
The FDA announced the approval of Tradjenta (linagliptin), made by Indianapolis-based Eli Lilly and German drug maker Boehringer Ingelheim.
“This approval provides another treatment option for the millions of Americans with Type 2 diabetes,” FDA Division of Metabolism and Endocrinology Products director Mary Parks said. “It is effective when used alone or when added to existing treatment regimens.”